标题
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
作者
关键词
-
出版物
Frontiers in Immunology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-03-20
DOI
10.3389/fimmu.2020.00492
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
- (2019) Daniel Jiahao Wong et al. Immunotherapy
- Nivolumab-refractory patients with advanced non-small-cell lung cancer
- (2019) A. Costantini et al. LUNG CANCER
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
- (2019) Zhi Ji et al. BMC CANCER
- Hyperprogression as a Distinct Outcome after Immunotherapy
- (2018) J. Fuentes-Antrás et al. CANCER TREATMENT REVIEWS
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC
- (2018) Pedro Rocha et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired resistance to cancer immunotherapy
- (2018) Arianna Draghi et al. Seminars in Immunopathology
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- (2018) Francesco Soria et al. WORLD JOURNAL OF UROLOGY
- Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression
- (2018) Furong Wang et al. Oncogenesis
- Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
- (2018) Marjorie Faure et al. Frontiers in Immunology
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
- (2018) Michäel Duruisseaux et al. Lancet Respiratory Medicine
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
- (2018) D R Gandara et al. ANNALS OF ONCOLOGY
- Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care
- (2018) Amanda Nizam et al. CANCER BIOLOGY & THERAPY
- Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism
- (2018) David A. Knorr et al. CLINICAL CANCER RESEARCH
- Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
- (2018) Julia L. Boland et al. GYNECOLOGIC ONCOLOGY
- Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients
- (2018) Taylor J Jensen et al. MOLECULAR CANCER THERAPEUTICS
- The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
- (2018) Chloé Grasselly et al. Frontiers in Immunology
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
- (2017) Maximilian J. Hochmair et al. LUNG CANCER
- The expanding role of innate lymphoid cells and their T-cell counterparts in gastrointestinal cancers
- (2017) Ka Yee Fung et al. MOLECULAR IMMUNOLOGY
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy for Colorectal Cancer
- (2017) Patrick Boland et al. Cancers
- Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
- (2017) Shilpa Gupta et al. Cancers
- Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
- (2016) Julie E. Bauman et al. CANCER
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
- (2016) Douglas G. McNeel et al. Journal for ImmunoTherapy of Cancer
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
- (2015) A. Ribas et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
- (2015) Mark A. Socinski SEMINARS IN ONCOLOGY
- NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
- (2015) Paolo Carrega et al. Nature Communications
- Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
- (2015) J. V. Cohen et al. Cancer Immunology Research
- Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
- (2013) Stefanie Kirchberger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Pseudoprogression and pseudoresponse in the treatment of gliomas
- (2009) Dieta Brandsma et al. CURRENT OPINION IN NEUROLOGY
- Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation
- (2008) Thomas Lehner IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now